IGM Biosciences Beheer

Beheer criteriumcontroles 2/4

De CEO IGM Biosciences is Mary Harler, benoemd in Oct2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.59% van de aandelen van het bedrijf, ter waarde $ 3.64M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 6 jaar.

Belangrijke informatie

Mary Harler

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	6yrs

Recente managementupdates

Recent updates

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Jan 05

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Sep 23

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Aug 29

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Aug 08

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Jun 09

IGM Biosciences: Interesting Science, Poor Trial Data

Feb 23

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?

Feb 17

Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Sep 07

IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

May 25

CEO

Mary Harler (59 yo)

less than a year

Tenure

Ms. Mary Beth Harler, M.D. is the Chief Executive Officer of IGM Biosciences, Inc. since October 01, 2024 and serves as its Director. She had been Head of Research & Autoimmunity at IGM Biosciences, Inc. s...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mary Harler	CEO & Director	less than a year	geen gegevens	0.59% $ 3.6m
Misbah Tahir	Chief Financial Officer	5.8yrs	US$1.08m	0.035% $ 218.6k
TS Harigopal	Senior Vice President of Group Operations	1.8yrs	geen gegevens	geen gegevens
Steven Weber	Senior VP	2.7yrs	geen gegevens	0.0043% $ 26.9k
Paul Graffagnino	Senior Vice President of Legal Affairs	3.8yrs	geen gegevens	geen gegevens
Suzette Tauber	Chief Human Resources Officer	5.4yrs	geen gegevens	geen gegevens
Angus Sinclair	Executive Vice President of Research	3.3yrs	geen gegevens	geen gegevens
Lisa Decker	Chief Business Officer	3.7yrs	US$4.92m	0.030% $ 187.9k
Marvin Peterson	Executive Vice President of Process Development & Manufacturing	3.6yrs	geen gegevens	geen gegevens
Elizabeth Haanes	Senior Vice President of Intellectual Property	2.6yrs	geen gegevens	geen gegevens
Elaine Sapinoso	Senior Vice President of Quality	1.8yrs	geen gegevens	geen gegevens
Faraz Siddiqui	Senior Vice President of Manufacturing Operations	1.3yrs	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IGMS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mary Harler	CEO & Director	no data	geen gegevens	0.59% $ 3.6m
Felix Baker	Independent Director	3.8yrs	US$168.55k	0.0037% $ 23.1k
M. Behrens	Independent Director	5.8yrs	US$178.30k	0.68% $ 4.2m
Mark Davis	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Rafi Ahmed	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Michael Lee	Independent Director	5.3yrs	US$166.09k	0.016% $ 97.2k
Jakob Topsoe	Independent Director	6.3yrs	US$166.09k	0.15% $ 921.2k
Julie Hambleton	Independent Director	6.3yrs	US$204.09k	0.0034% $ 20.8k
Christina Topsoe	Independent Director	6.3yrs	US$175.84k	0.099% $ 613.1k
William Strohl	Independent Director	6.3yrs	US$236.59k	0% $ 0
Elizabeth Thompson	Independent Director	1.1yrs	US$167.54k	0.0073% $ 45.5k
Gordon J. Freeman	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IGMS wordt beschouwd als ervaren (gemiddelde ambtstermijn 6 jaar).

IGM Biosciences Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

Independent Director notifies of intention to sell stock

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

CEO, President & Director recently sold US$90k worth of stock

Insufficient new directors

IGM Biosciences, Inc. Announces Board Changes

Recent updates

Consensus revenue estimates increase by 16%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Consensus revenue estimates decrease by 74%

Price target decreased by 13% to US$19.10

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

IGM Biosciences: Waiting For Godot

Consensus revenue estimates increase by 281%

Consensus revenue estimates fall by 95%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

IGM Biosciences, Inc. Provides Pipeline Updates

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 1,210%

IGM Biosciences: Unlikely To Move The Needle Again In 2024

First quarter 2024 earnings released: US$0.83 loss per share (vs US$1.33 loss in 1Q 2023)

IGM Biosciences, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

New major risk - Share price stability

CEO, President & Director recently sold US$90k worth of stock

Consensus EPS estimates upgraded to US$3.26 loss

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%

Consensus revenue estimates decrease by 13%, EPS upgraded

We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

IGM Biosciences, Inc. Announces Board Changes

Price target decreased by 7.8% to US$30.09

New minor risk - Shareholder dilution

IGM Biosciences, Inc. announced a financing transaction

IGM Biosciences, Inc. Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

Consensus revenue estimates decrease by 43%, EPS upgraded

We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn

Consensus revenue estimates decrease by 50%

Price target decreased by 17% to US$32.64

IGM Biosciences Initiates First-In-Human Clinical Trial of Igm-7354 in Solid Tumors

IGM Biosciences Announces Update on Igm-8444 Phase 1 Trial and Future Clinical Development

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

CEO, President & Director recently sold US$235k worth of stock

CEO, President & Director notifies of intention to sell stock

Independent Director recently bought US$1.0m worth of stock

Insufficient new directors

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer exercised options and sold US$548k worth of stock

Independent Chairman of the Board recently bought US$140k worth of stock

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Chief Scientific Officer exercised options and sold US$460k worth of stock

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Chief Scientific Officer exercised options and sold US$531k worth of stock

Price target decreased to US$43.78

Consensus revenue estimates fall by 98%

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Insufficient new directors

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

IGM Biosciences, Inc. Appoints Steven Weber as Principal Accounting Officer

Independent Director recently bought US$234k worth of stock

Consensus revenue estimates fall by 86%

Price target decreased to US$52.78

Chief Scientific Officer exercised options and sold US$60k worth of stock

Independent Director recently bought US$1.4m worth of stock

Price target decreased to US$52.78

Chief Scientific Officer exercised options and sold US$207k worth of stock

Price target decreased to US$57.89

IGM Biosciences: Interesting Science, Poor Trial Data

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?